Findings

What do systematic reviews say?

17 questions · 18 findings · 9 reviews · Airways

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 2 · 11.1%Low 3 · 16.7%Moderate 5 · 27.8%High 8 · 44.4%

Mepolizumab intravenous (IV) vs placebo

Health‐related quality of life (ACQ) Scale from: 0 to 6 (lower is better) · people with asthma

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 369 participants
High

Mepolizumab subcutaneous (SC) vs placebo

Health‐related quality of life (ACQ) Scale from: 0 to 6 (lower is better) · people with asthma

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1231 participants
High

Benralizumab subcutaneous (SC) vs placebo

Health‐related quality of life (ACQ) Scale from: 0 to 6 (lower is better) · people with asthma

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 2791 participants
High

Reslizumab intravenous (IV) vs placebo

Health‐related quality of life (ACQ) Scale from: 0 to 6 (lower is better) · people with asthma

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 1652 participants
High

Reslizumab subcutaneous (SC) vs placebo

Health‐related quality of life (ACQ) Scale from: 0 to 6 (lower is better) · people with asthma

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 464 participants
High

Mepolizumab subcutaneous (SC) vs placebo

SGRQ Total SGRQ (Total) Score. Scale from: 0 to 100. Lower score indicates better quality of life. · people with asthma

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1231 participants
High

Reslizumab subcutaneous (SC) vs placebo

SGRQ Total SGRQ (Total) Score. Scale from: 0 to 100. Lower score indicates better quality of life. · people with asthma

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 464 participants
High

Summary of findings ‐ Inhaled mannitol vs placebo

SGRQ Total SGRQ (Total) Score. Scale from: 0 to 100. Lower score indicates better quality of life. · people with bronchiectasis

Inhaled mannitol showed no clear difference in health‐related quality of life measured on the SGRQ Scale from 0 to… compared with placebo (moderate certainty).

1 finding from 1 review

Inhaled hyperosmolar agents for bronchiectasis 2014 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 840 participants
Moderate

Mepolizumab 100 mg vs placebo

Change in SGRQ total score · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1285 participants
Moderate

Mepolizumab 300 mg vs placebo

QoL · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 451 participants
Moderate

Mepolizumab 100 mg vs placebo

QoL · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 911 participants
Moderate

Mucolytic vs placebo

SGRQ Total SGRQ (Total) Score. Scale from: 0 to 100. Lower score indicates better quality of life. · chronic bronchitis or COPD

1 finding from 1 review

Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 2721 participants
Moderate

Pursed lip breathing vs no breathing exercises

Health‐related quality of life Dyspnoea domain of Hiratsuka scale Scores range from 0 to 100, with lower scores indicating less shortness of breath · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Breathing exercises for chronic obstructive pulmonary disease 2012 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 60 participants
Low

Intervention not reported

Health‐related quality of life (disease‐specific) Scale from 0 to 100; lower score indicates better HRQoL. SGRQ total score consists of weighted scores from 3 domains · individuals with stable bronchiectasis

1 finding from 1 review

Airway clearance techniques for bronchiectasis 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 20 participants
Low

Intervention not reported

Health‐related quality of life (respiratory specific) St George's Respiratory Questionnaire (SGRQ; total score) Scale from 0‐100 Lower value post intervention is favourable, indicating improvement in health‐related quality of life · people with stable COPD

1 finding from 1 review

Singing for adults with chronic obstructive pulmonary disease 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 58 participants
Low

Summary of Findings Table ‐ Chronic non‐invasive ventilation vs standard treatment following a severe exacerbation

Change in the health‐related quality of life · post‐exacerbation COPD

2 findings from 1 review

Chronic non‐invasive ventilation for chronic obstructive pulmonary disease 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 219 participants
Very low
Chronic non‐invasive ventilation for chronic obstructive pulmonary disease 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 164 participants
Very low

Pulmonary rehabilitation vs usual care

Health‐related quality of life Change in total score of St George Respiratory Questionnaire · post‐exacerbation COPD

1 finding from 1 review

Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease 2016 · Cochrane Headline outcomes only
no estimate extracted
8 studies · 1003 participants
High